Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial
Source: View publication →
The THRACE trial demonstrated that the addition of mechanical thrombectomy to standard intravenous thrombolysis improves functional independence at 3 months compared to intravenous thrombolysis alone in patients with acute ischemic stroke due to proximal cerebral artery occlusion.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial reinforces the paradigm of 'bridging therapy' for large-vessel occlusion ischemic strokes, supporting the use of mechanical thrombectomy in addition to standard intravenous thrombolysis within 5 hours of symptom onset.
Historical Context
Designed in 2009, THRACE sought to clarify the benefit of endovascular therapy in the era before widespread clinical adoption, ultimately contributing to the robust body of evidence alongside trials like MR CLEAN, ESCAPE, and SWIFT PRIME that established mechanical thrombectomy as the standard of care.
Guided Discussion
High-yield insights from every perspective
Explain the physiological rationale behind why mechanical thrombectomy is more effective than intravenous alteplase (IVT) alone for proximal large vessel occlusions (LVOs).
Key Response
Large clots in the proximal arteries (like the M1 segment of the MCA) have a high burden of fibrin and platelets that IVT often fails to fully dissolve within the critical window. Mechanical thrombectomy physically removes the obstruction, providing near-instantaneous recanalization, which is crucial because approximately 1.9 million neurons are lost for every minute of ischemia.
In the context of the THRACE trial results, how should a clinician prioritize the administration of IV alteplase versus transferring a patient for mechanical thrombectomy?
Key Response
THRACE confirms the benefit of combined therapy. Current guidelines (AHA/ASA) emphasize that IV alteplase should be initiated as soon as possible ('drip-and-ship' or 'mothership' models) and should not be delayed while waiting for endovascular intervention, as IVT can sometimes achieve early recanalization or soften the thrombus for easier mechanical retrieval.
The THRACE trial included patients with a wide variety of mechanical devices. How does the evolution from first-generation devices to modern stent-rievers and large-bore aspiration catheters impact the generalizability of THRACE's reported effect sizes today?
Key Response
THRACE was conducted during a transition period in endovascular technology. While it proved the superiority of the endovascular approach, modern devices achieve higher first-pass TICI 2b/3 reperfusion rates than those used in the early stages of the trial, suggesting that current clinical outcomes in practice may actually exceed the original trial's conservative estimates.
THRACE was stopped early for efficacy. How do you communicate the 'Number Needed to Treat' (NNT) for functional independence to a family when discussing the risks of procedural complications versus the benefits of the intervention?
Key Response
The THRACE trial demonstrated an absolute benefit of 11.1% for functional independence (mRS 0-2), which translates to an NNT of approximately 9. Teaching points should focus on the fact that while procedural risks exist, the high likelihood of avoiding severe disability makes thrombectomy the ethical standard of care for eligible LVO patients.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
THRACE utilized a group sequential design with an alpha-spending function. What are the statistical implications of stopping a trial early for efficacy regarding the precision of the point estimate for the primary endpoint?
Key Response
Stopping early for efficacy often leads to 'over-optimism' or an inflation of the treatment effect size. From a methodological standpoint, while the result is statistically significant, the confidence intervals are often wider than they would have been at full enrollment, necessitating meta-analyses (like the HERMES collaboration) to determine the true stable effect size.
A major concern in open-label trials like THRACE is the potential for bias in outcome assessment. How does the study's use of a 'PROBE' design (Prospective Randomized Open-label Blinded Endpoint) address concerns regarding the validity of the 3-month modified Rankin Scale scores?
Key Response
The PROBE design mitigates observer bias by ensuring that the person assessing the functional outcome (the mRS) is unaware of the patient's treatment assignment. A journal editor would scrutinize whether the blinding of these assessors was truly maintained and if any post-randomization exclusions occurred that could favor the intervention group.
How do the findings of THRACE, specifically regarding the safety profile (symptomatic intracranial hemorrhage rates), influence the Level of Evidence for bridging therapy in international stroke guidelines?
Key Response
THRACE showed that the addition of mechanical thrombectomy did not significantly increase the rate of symptomatic intracranial hemorrhage compared to IVT alone (approx. 2% vs 1%). This contributed to the Class I, Level A recommendation in AHA/ASA guidelines that endovascular therapy is safe and highly effective when added to standard medical care for patients meeting specific imaging and clinical criteria.
Clinical Landscape
Noteworthy Related Trials
MR CLEAN Trial
Tested
Mechanical thrombectomy plus usual care
Population
Patients with acute ischemic stroke due to proximal arterial occlusion in the anterior circulation
Comparator
Usual care alone
Endpoint
Functional independence (modified Rankin Scale score 0-2 at 90 days)
ESCAPE Trial
Tested
Mechanical thrombectomy with the use of standard care and imaging-based selection
Population
Patients with acute ischemic stroke with proximal vessel occlusion and small infarct core
Comparator
Standard care alone
Endpoint
Functional independence (modified Rankin Scale score 0-2 at 90 days)
SWIFT PRIME Trial
Tested
Solitaire stent retriever thrombectomy plus intravenous t-PA
Population
Patients with acute ischemic stroke with moderate-to-severe neurological deficits and occlusion of the internal carotid or middle cerebral artery
Comparator
Intravenous t-PA alone
Endpoint
Functional independence (modified Rankin Scale score 0-2 at 90 days)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis